In February, 2021, researchers from Spain conducted a study published in Oncotarget, titled: “Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach.”

This trending paper was authored by researchers practicing at the Hospital Germans Trias i Pujol, Takeda Farmacéutica España, Anaxomics Biotech, and Universitat Pompeu Fabra.

The researchers used a computer simulated modeling system to highlight the strengths and weaknesses of two ALK inhibitors. They first began their study by characterizing the pathophysiology of ALK+ NSCLC after completing a detailed review of review papers published in PubMed between 2013 and 2018.

Read the full study here: https://www.oncotarget.com/article/27875/text/

The Trending with Impact series highlights Oncotarget publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels.

More from Trending with Impact: www.oncotarget.org/tag/trending-with-impact/

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105